BioNotebook: Alector, Dimension, Discovery Labs, BioMarin/Clovis, Array, CEL-SCI, Otonomy, GlobeImmune
This article was originally published in Scrip
Executive Summary
Alector, Dimension raise Series A rounds; Discovery Labs sells $50m in stock; BioMarin, Clovis start PARP inhibitor studies; Array takes ARRY-502 into Phase III; CEL-SCI seeks arbitration with CRO; Otonomy buys tinnitus IP; and GlobeImmune withdraws IPO.